Neoadjuvant chemotherapy weakens the prognostic value of the pathological tumor burden score for colorectal cancer liver metastases

Table 1 Clinicopathologic characteristics of 348 consecutive CRLM patients who underwent primary tumor

Characteristics	No. of patients (%)
Patient characteristics
Median age (years)	57(49–64)
Gender
Male Female	231(66.4) 117(33.6)
Primary tumor location
Colon Rectum	220(63.2) 128(36.8)
T stage
T1-3 T4	209(60.1) 139(39.9)
Nodal metastases
Positive Negative	216(62.1) 132(37.9)
Primary tumor differentiation
Well to moderate Poor	264(75.9) 84(24.1)
Timing of metastasis
Synchronous Metachronous	239(68.7) 109(31.3)
RECIST response^a
SD or PD PR	61(37.7) 101(62.3)
Preoperative CEA (ng/mL)^b
≤ 5 > 5	131(39.8) 198(60.2)
Preoperative CA19-9 (U/ml)^c
≤ 35 > 35	221(69.1) 99(30.9)
Number of liver metastases, median (IQR)	2(1–3)
Size of largest liver metastasis(cm), median(IQR)	2.5(1.5–3.8)
TBS, median(IQR)	3.2(2.2–5.1)
Tumor distribution
Unilobar	245
Bilobar	103
KRAS mutation status^d
Wild-type Mutation-type	55 34
Postoperative chemotherapy
Yes No	245 103

CRLMs, colorectal liver metastases; TNM stage, tumor-node-metastasis classification; IQR, interquartile range; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19 − 9; TBS, tumor burden score; RECIST, Response Evaluation Criteria in Solid Tumor; SD, stable disease; PD, progressive disease; PR, partial response;
^a Data were available for 162 patients
^b Data were available for 329 patients
^c Data were available for 320 patients
^d Data were available for 89 patients

ISSN: 1471-2482